Journals / Türk Oftalmoloji Dergisi / 2013 / Cilt: 43 - Sayı: 5

Tear film and ocular surface changes in patients receiving systemic ısotretinoin

Sistemik isotretinoin tedavisi alan hastalarda gözyaşı ve oküler yüzey değişiklikleri

Pages
309–312
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Dis­cus­si­on: Systemic isotretinoin treatment can cause alterations in the tear film and cause dry eye symptoms. (Turk J Ophthalmol 2013; 43: 309-12)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pur­po­se: Our aim in this study was to assess the ocular surface and tear film changes in acne vulgaris patients receiving systemic isotretinoin.
📊
Key Findings & Data:Ma­te­ri­al and Met­hod: Twenty-two eyes of 22 patients who received oral isotretinoin (roaccutane®, 0.7 mg/kg/day) for nodular acne vulgaris were enrolled in this prospective study.
💡
Conclusion & Impact:Dis­cus­si­on: Systemic isotretinoin treatment can cause alterations in the tear film and cause dry eye symptoms. (Turk J Ophthalmol 2013; 43: 309-12)
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Pur­po­se: Our aim in this study was to assess the ocular surface and tear film changes in acne vulgaris patients receiving systemic isotretinoin. Ma­te­ri­al and Met­hod: Twenty-two eyes of 22 patients who received oral isotretinoin (roaccutane®, 0.7 mg/kg/day) for nodular acne vulgaris were enrolled in this prospective study. Tear film break-up time (BUT), Schirmer 1 test scores with anesthesia, ocular surface disease index (OSDI) scores and conjunctival impression cytology scores were recorded before treatment and at 3- and 6-month visits following the beginning of treatment. Re­sults: BUT values decreased and OSDI scores significantly increased at 3 months after treatment (p=0.007 and p=0.018, paired samples test). Schirmer scores did not significantly change by isotretinoin treatment. Of 9 eyes with impression cytology specimens, 4 revealed normal conjunctival findings before treatment. At the 3rd month, there was an increase in the scores characterized by decrease of Goblet cells, and at 6 months of treatment, normal conjunctival findings did not exist in any of the patients (p=0.004, Friedman test). Dis­cus­si­on: Systemic isotretinoin treatment can cause alterations in the tear film and cause dry eye symptoms. (Turk J Ophthalmol 2013; 43: 309-12)

Özet

Amaç: Bu çalışmadaki amacımız sistemik isotretinoin tedavisi alan akne vulgaris hastalarında gözyaşı tabakası ve oküler yüzey değişikliklerinin raştırılmasıdır. Ge­reç ve Yön­tem: Prospektif olarak gerçekleştirilen bu çalışmaya oral isotretinoin (roaccutane®, 0,7 mg/kg/gün) tedavisi başlanan 22 nodüler akne vulgaris hastasının 22 gözü dahil edildi. Tedavi öncesinde, tedavinin 3. ve 6. ayında, gözyaşı filmi kırılma zamanı (GKZ), anestezili Schirmer 1 testi, oküler yüzey hastalık indeksi (OYHI) ve konjonktival impresyon sitolojisi skorları kaydedildi. Sonuçlar: Tedavinin 3. ayında GKZ değerlerinde azalma ve OYHI skorlarında artış saptandı (p=0,007 ve p=0,018, eşleştirilmiş t testi). Schirmer korlarında ise anlamlı bir değişiklik görülmedi. İmpresyon sitoloji örneği bulunan 9 hastanın 4ünde tedavi öncesinde normal konjonktiva bulguları aptandı. Tedavinin 3. ayında, Goblet hücrelerinde azalmayı gösteren skor artışı izlendi ve 6. ayda hiçbir hastada normal konjonktiva bulgularının bulunmadığı görüldü (p=0,004, Friedman testi). Tar­t fl­ma: Sistemik isotretinoin tedavisi gözyaşı filminde değişikliklere ve kuru göz semptomlarına yol açmaktadır. (Turk J Ophthalmol 2013; 43: 309-12)

🔖

Cite This Article

BİR, F., KAÇAR, N., YALDIZKAYA, F., NEVİN, E. Ç., ŞANLI, B., YAYLALI, V. (2022). Tear film and ocular surface changes in patients receiving systemic ısotretinoin. Türk Oftalmoloji Dergisi, Cilt: 43 - Sayı: 5, 309–312. https://ajindex.com/articles/638207

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 2001;132:299-305.
  2. Mathers WD, Shields WJ, Sachdev MS, Petroll WM, Jester JV. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea. 1991;10:286-90. Shalita AR. Mucocutaneous and systemic toxicity of retinoids: monitoring and management. Dermatologica. 1987;175:151-7.
  3. Rismondo V, Ubels JL: Isotretinoin in lacrimal gland fluid and tears. Arch Ophthalmol. 1987;105:416-20.
  4. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615-21.
  5. Nelson JD, Wright JC. Conjunctival goblet cell densities in ocular surface disease. Arch Ophthalmol. 1984;102:1049-51.
  6. Lambert RW, Smith RE. Pathogenesis of blepharoconjunctivitis complicating 13-cis-retinoic acid (isotretinoin) therapy in a laboratory model. Invest Ophthalmol Vis Sci. 1988;29(10):1559-64.
  7. Evren Ö, Karcı AA, Orhan İ, Artüz F, Tamer U, Şener B, GürselRoaccutane Tedavisinin Göz Yaşı Fonksiyonları ve Meibomian Bezi Lipid Yapısına Etkisi. MN Oftalmoloji. 2005;12(4):304-8. de Queiroga IB, Antônio Vieira L, Barros Jde N, Melo Diniz Mde F, de Morais LC. Conjunctival impression cytology changes induced by oral isotretinoin. Cornea. 2009;28:1009-13.
  8. Karalezli A, Borazan M, Altinors DD, Dursun R, Kiyici H, Akova YA. Conjunctival impression cytology, ocular surface, and tear-film changespatients treated with systemic isotretinoin. Cornea. 2009;28:46-50.
  9. Egger SF, Huber-Spitzy V, Böhler K et al. Ocular side effects associated with 13-cis-retinoic acid therapy for acne vulgaris: clinical features, alterations tearfilm and conjunctival flora. Acta Ophthalmol Scand. 1995;73:355-7.
  10. Aragona P, Cannavò SP, Borgia F, Guarneri F. Utility of studying ocular surface in patients with acne vulgaris treated with oral isotretinoin: randomized controlled trial. Br J Dermatol. 2005;152:576-8.
  11. Oner A, Ferahbas A, Karakucuk S. Ocular side effects associated with systemic isotretinoin.Journal of toxicology, Cutaneous and ocular toxicology 2004; 23:189-95.
  12. Cumurcu T, Sezer E, Kilic R, Bulut Y. Comparison of dose-related ocular side effects during systemic isotretinoin administration. Eur J Ophthalmol. 2009;19:196-200
  13. Bozkurt B, Irkeç MT, Atakan N, Orhan M, Geyik PO. Lacrimal function and ocular complications in patients treated with systemic isotretinoin. EurOphthalmol 2002;12:173-6. Sengor T,